TW200503694A - Triazole-derivatives as factor Xa inhibitors - Google Patents

Triazole-derivatives as factor Xa inhibitors

Info

Publication number
TW200503694A
TW200503694A TW093113794A TW93113794A TW200503694A TW 200503694 A TW200503694 A TW 200503694A TW 093113794 A TW093113794 A TW 093113794A TW 93113794 A TW93113794 A TW 93113794A TW 200503694 A TW200503694 A TW 200503694A
Authority
TW
Taiwan
Prior art keywords
factor
compounds
formulae
inhibitors
triazole
Prior art date
Application number
TW093113794A
Other languages
English (en)
Chinese (zh)
Inventor
Marc Nazare
Volker Laux
Armin Bauer
Michael Wagner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of TW200503694A publication Critical patent/TW200503694A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093113794A 2003-05-19 2004-05-17 Triazole-derivatives as factor Xa inhibitors TW200503694A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors

Publications (1)

Publication Number Publication Date
TW200503694A true TW200503694A (en) 2005-02-01

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093113794A TW200503694A (en) 2003-05-19 2004-05-17 Triazole-derivatives as factor Xa inhibitors

Country Status (12)

Country Link
EP (2) EP1479679A1 (https=)
JP (1) JP4608495B2 (https=)
AT (1) ATE394396T1 (https=)
AU (1) AU2004238498B2 (https=)
BR (1) BRPI0410763A (https=)
CA (1) CA2526082C (https=)
DE (1) DE602004013577D1 (https=)
IL (1) IL171843A (https=)
MX (1) MXPA05012058A (https=)
PE (1) PE20050154A1 (https=)
TW (1) TW200503694A (https=)
WO (1) WO2004101555A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
RS54303B1 (sr) * 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-člani heterociklični amidi i srodna jedinjenja
WO2009038157A1 (ja) 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. 2,3-ジヒドロ-イミノイソインドール誘導体
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) * 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
IL136637A0 (en) * 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
DE602004013577D1 (de) 2008-06-19
IL171843A (en) 2010-12-30
JP4608495B2 (ja) 2011-01-12
MXPA05012058A (es) 2006-06-23
JP2006528941A (ja) 2006-12-28
WO2004101555A1 (en) 2004-11-25
EP1628971B1 (en) 2008-05-07
BRPI0410763A (pt) 2006-08-01
ATE394396T1 (de) 2008-05-15
CA2526082C (en) 2012-07-24
EP1479679A1 (en) 2004-11-24
AU2004238498A1 (en) 2004-11-25
AU2004238498B2 (en) 2010-07-22
CA2526082A1 (en) 2004-11-25
PE20050154A1 (es) 2005-04-29
EP1628971A1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
MXPA04004797A (es) Indol-2-carboxamidas como inhibidores del factor xa.
TW200510400A (en) Indazole-derivatives as factor Xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
TW200510393A (en) New indole derivatives as factor Xa inhibitors
WO2005085239A3 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
PL362519A1 (en) Oxybenzamides derivatives as factor xa inhibitors
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
MXPA03011022A (es) Derivados de urea con actividad antiproteolitica.
TW200503694A (en) Triazole-derivatives as factor Xa inhibitors
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200503696A (en) Benzimidazole-derivatives as factor Xa inhibitors
TW200510411A (en) Azaindole-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors